IPOPI takes part in the HTA Stakeholder Network meeting

December 16, 2024

IPOPI takes part in the HTA Stakeholders Network Meeting

IPOPI has taken part in a meeting of the HTA Stakeholder Network on November 29, 2024, in Brussels. The meeting was very well attended with representatives from EU Member States, patient organisations, healthcare professionals, developers of medicines and medical devices and consumer organisations. The objective of the meeting was to discuss, with the network, the steps taken for the EU and member states to get ready for the legislation to enter into force and also to hear the stakeholders’ views on specific items of relevance to HTA assessors.

IPOPI has recently joined the Health Technology Assessment (HTA) Stakeholder Network, a body that gathers organisations that have an interest in HTA and that wish to provide input to the representatives of Member States dealing with European HTAs. IPOPI representatives in this network are Leire Solis, the senior manager of health policy and advocacy, and Martine Pergent, the president.

This network is of particular relevance, as a joint HTA will become mandatory at the EU level in different phases:

From January 2025, for medicines for cancer treatment and advanced therapies.
From January 2028, for orphan medicinal products.
From January 2030, for all products (medicines and some medical devices).

It is considered that having a joint EU HTA will facilitate equity in access to therapies as well as quicker access to new technologies. Although the assessment on the scientific and clinical characteristics of the medicine or device will be the same, the interpretation that Member States can do of this information may vary from one country to another.